Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

Day: April 22, 2025

Endocrinology

Endocrinology Weekly Update - 22nd April 2025

🔬 Endocrinology Updates You Shouldn't Miss: Hormonal Health, Diabetes Risk…

Obesity Weekly News

Obesity Weekly News - April 22nd 2025

💊 Obesity Watch: GLP-1 Pills, Trial Updates & Global Market Moves …

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Vaccines Today—April 3, 2026
Public Health Today—April 3, 2026
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Cardiovascular Today—April 2, 2026

Tags

AI-native clinical development Alpibectir-Ethionamide Amlenetug AMXT 1501 Astellas Gene Therapies BBM-H901 Candel Therapeutics Centre For Chronic Disease Control Chronic disease mortality conduction-system pacing cost reduction CUF dialysis DIPS Arena Elecsys AMH Plus Electrocardiogram Patch Emboline Enzalutamide FDA Digital Health Advisory FG001 FIGO Glanzmann Thrombasthenia GLP-1 Receptor Agonists gout flares hypertension guidelines Jaypirca live biotherapeutic product MicroRNAs naxtarubicin OCALIVA PPMS QRX003 ralinepag Receptor.AI Rinvoq Rituximab Spikevax Stanford Medicine Sutra Medical Terns Pharmaceuticals TG Therapeutics Transgene VCN-01 Ver-A-T1D Z-Basivarsen

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Vaccines Today—April 3, 2026
Public Health Today—April 3, 2026
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Cardiovascular Today—April 2, 2026

TAGS

AI-native clinical development Alpibectir-Ethionamide Amlenetug AMXT 1501 Astellas Gene Therapies BBM-H901 Candel Therapeutics Centre For Chronic Disease Control Chronic disease mortality conduction-system pacing cost reduction CUF dialysis DIPS Arena Elecsys AMH Plus Electrocardiogram Patch Emboline Enzalutamide FDA Digital Health Advisory FG001 FIGO Glanzmann Thrombasthenia GLP-1 Receptor Agonists gout flares hypertension guidelines Jaypirca live biotherapeutic product MicroRNAs naxtarubicin OCALIVA PPMS QRX003 ralinepag Receptor.AI Rinvoq Rituximab Spikevax Stanford Medicine Sutra Medical Terns Pharmaceuticals TG Therapeutics Transgene VCN-01 Ver-A-T1D Z-Basivarsen

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy